logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 11 of 11 Items
Showing 1 - 11 of 11 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Four-month high-dose rifampicin regimens for pulmonary tuberculosis

Jindani A, Atwine D, Grint D, Bah B, Adams J,  et al.
2023-09-01 • NEJM Evidence
2023-09-01 • NEJM Evidence
BACKGROUND
Shorter but effective tuberculosis treatment regimens would be of value to the tuberculosis treatment community. High-dose rifampicin has been associated with more rapid a...
Journal Article
|
Research

Southern african HIV clinicians society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update

Govender NP, Meintjes GA, Mangena PM, Nel J, Potgieter S,  et al.
2019-11-08 • Southern African Journal of HIV medicine
2019-11-08 • Southern African Journal of HIV medicine
Journal Article
|
Research

Time to embrace access programmes for medicines: Lessons from the South African flucytosine access programme

Shroufi A, Govender NP, Meintjes GA, Black JM, Nel J,  et al.
2020-06-01 • International Journal of Infectious Diseases
2020-06-01 • International Journal of Infectious Diseases
BACKGROUND
Cryptococcal Meningitis (CM) is estimated to cause 181,000 deaths annually; with the majority occurring in Sub Saharan Africa. Flucytosine is recommended by the World Heal...
Journal Article
|
Research

A clinical severity scoring system for visceral leishmaniasis in Immunocompetent patients in South Sudan

Kamink SS, Collin SM, Harrison TS, Gatluak F, Mullahzada AW,  et al.
2017-10-02 • PLOS Neglected Tropical Diseases
2017-10-02 • PLOS Neglected Tropical Diseases
BACKGROUND
South Sudan is one of the most endemic countries for visceral leishmaniasis (VL), and is frequently affected by large epidemics. In resource-limited settings, clinicians r...
Journal Article
|
Commentary

Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries

Loyse A, Burry J, Cohn J, Ford NP, Chiller T,  et al.
2018-10-18 • Lancet Infectious Diseases
2018-10-18 • Lancet Infectious Diseases
In 2018, WHO issued guidelines for the diagnosis, prevention, and management of HIV-related cryptococcal disease. Two strategies are recommended to reduce the high mortality associated w...
Journal Article
|
Research

A randomised phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis

Jindani A, Borgulya G, de Patino IW, Gonzales T, de Fernandes RA,  et al.
2016-06-01 • International Journal of Tuberculosis and Lung Disease
2016-06-01 • International Journal of Tuberculosis and Lung Disease
SETTING
Randomised Phase IIB clinical trial.

OBJECTIVES
To assess whether increasing the dose of rifampicin (RMP) from 10 mg/kg to 15 or 20 mg/kg results in an increase ...
Journal Article
|
Research

Outcomes of visceral leishmaniasis in pregnancy: A retrospective cohort study from South Sudan

Pekelharing JE, Gatluak F, Harrison TS, Maldonado F, Siddiqui MR,  et al.
2020-01-24 • PLOS Neglected Tropical Diseases
2020-01-24 • PLOS Neglected Tropical Diseases
INTRODUCTION
Visceral leishmaniasis (VL) is endemic in South Sudan, where outbreaks occur frequently. Because of changes in the immune system during pregnancy, pregnant women are con...
Journal Article
|
Commentary

Cryptococcal meningitis: A neglected NTD?

Molloy SF, Chiller T, Greene GS, Burry J, Govender NP,  et al.
2017-06-29 • PLOS Neglected Tropical Diseases
2017-06-29 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study

Mashau RC, Meiring ST, Quan VC, Nel J, Greene GS,  et al.
2022-06-21 • Lancet Infectious Diseases
2022-06-21 • Lancet Infectious Diseases
BACKGROUND
Although flucytosine is a key component of WHO-recommended induction treatment for HIV-associated cryptococcal meningitis, this antifungal agent is not widely available in...
Journal Article
|
Review

Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries

Loyse A, Thangaraj H, Easterbrook PJ, Ford NP, Roy M,  et al.
2013-05-31 • Lancet Infectious Diseases
2013-05-31 • Lancet Infectious Diseases
Cryptococcal meningitis is the leading cause of adult meningitis in sub-Saharan Africa, and contributes up to 20% of AIDS-related mortality in low-income and middle-income countries ever...
Journal Article
|
Commentary

Ending deaths from HIV-related cryptococcal meningitis by 2030

Shroufi A, Chiller T, Jordan A, Denning DW, Harrison TS,  et al.
2021-01-01 • Lancet Infectious Diseases
2021-01-01 • Lancet Infectious Diseases
The UNAIDS target to reduce HIV-related death to fewer than 500 000 deaths per year by 2020 will not be met. 1 This statement might not be headline grabbing as this target was never as p...